Abstract:ObjectiveTo approach clinical effect of whole-body vertical vibration combined with kinesitherapy in the treatment of Parkinson′s disease.MethodsThe clinical data of 52 patients with Parkinson′s disease in Rehabilitation Department of the Second People′s Hospital in Zhanjiang City were analyzed,which was to be divided into two group by different treatment method,control group(drug+acupuncture treatment,26 cases)and detection group(kinesitherapy combined with whole-body vertical vibration treatment,26 cases)the UPDRS score and Fugl-Meyer equilibrium function score of two group parkinson patients before treatment and after treatment were detected,the clinical effects,recurrence rate of two group parkinson patients were detected.ResultsThe difference of UPDRS score and Fugl-Meyer equilibrium function score for two group parkinson patients before treatment were no statistical significance (P>0.05),the UPDRS score of two group patients after treatment were lower than before treatment,the Fugl-Meyer equilibrium function score were higher than before treatment,the UPDRS score of detection group patients after treatment were lower than control group,the Fugl-Meyer equilibrium function score were higher than control group,the clinical treatment total effective rate of detection group patients was higher than control group,the recurrence rate of detection group patients was lower than control group,the differences were statistical significance (P<0.05).ConclusionWhole-body vertical vibration combined with kinesitherapy treat Parkinson′s disease,clinical symptoms improve obviously,the clinical effects is good,it is worth to be used.
黄树敏;陈明华. 运动疗法结合全身垂直律动治疗帕金森病的临床效果[J]. 中国当代医药, 2018, 25(18): 52-54.
HUANG Shu-min;CHEN Ming-hua. The clinical effect of whole-body vertical vibration combined with kinesitherapy in the treatment of Parkinson′s disease. 中国当代医药, 2018, 25(18): 52-54.
Sun Z,Jia J,Gong X,et al.Inhibition of glutamate and acetylcholine release in behavioral improvement induced by electroacupuncture in parldnsonian rats[J].Neurosci Lett,2012,520(1):32-37.
Bansal S,Hirdes JP,Maxwell CJ,et al.Identifying Fallers among Home Care Clients with Dementia and Parkinson′s Disease[J].Can J Aging,2016,35(3):319-331.
[11]
Guella I,Evans DM,Szu-Tu C,et al.A-synuclein genetic variability:A biomarker for dementia in Parkinson disease[J].Ann Neurol,2016,79(6):991-999.
[12]
Colloby SJ,McKeith IG,Burn DJ,et al.Cholinergic and perfusion brain networks in Parkinson disease dementia[J].Neurology,2016,87(2):178-185.
[13]
Pagan F,Hebron M,Valadez EH,et al.Nilotinib Effects in Parkinson′s disease and Dementia with Lewy bodies[J].J Parkinsons Dis,2016,6(3):503-517.
[14]
Delgado-Alvarado M,Gago B,Navalpotro-Gomez I,et al.Biomarkers for dementia and mild cognitive impairment in Parkinson′s disease[J].Mov Disord,2016,31(6):861-881.